Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C-Reference-Cited by-同舟云学术

Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C

Published:2008-01 Issue:1 Volume:38 Page:52-59
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Hiramatsu Naoki,Kurashige Nao,Oze Tsugiko,Takehara Tetsuo,Tamura Shinji,Kasahara Akinori,Oshita Masahide,Katayama Kazuhiro,Yoshihara Harumasa,Imai Yasuharu,Kato Michio,Kawata Sumio,Tsubouchi Hirohito,Kumada Hiromitsu,Okanoue Takeshi,Kakumu Shinichi,Hayashi Norio

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1872-034X.2007.00205.x/fullpdf

Reference27 articles.

1. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C

2. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response

3. Antiviral therapy for chronic hepatitis C: past, present, and future

4. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

5. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reticulocyte production index as a predictor of clinically significant anemia in chronic hepatitis C patients receiving pegylated interferon combination therapy;Advances in Digestive Medicine;2015-04-22

2. Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1;Journal of Medical Virology;2015-01-21

3. Model incorporating theITPAgenotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C;Journal of Medical Virology;2013-01-07

4. Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients;World Journal of Gastroenterology;2013

5. Guidelines for the Management of Hepatitis C Virus Infection;Hepatology Research;2013-01